Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025European Journal of RadiologyOpen Access

Gadolinium concentration dependent signal enhancement profiles using routine clinical sequences with gadopiclenol, gadoterate, gadobutrol, and gadoxetate at 1.5, 3 and 7 Tesla

View Full Paper
Ask AI
Bookmark
Share

Authors

TMThomas MarthJFJohannes M. FroehlichDNDaniel Nanz

Discussion

Loading...

Member takes

Overview

Analysis compares gadopiclenol with standard GBCAs to enhance MRI T1-weighted signal, suggesting lower concentrations may suffice.

Key Points

  • Gadopiclenol shows a higher longitudinal relaxivity than standard contrast agents, enhancing signal at lower doses.
  • The maximum relative signal intensity for gadopiclenol at 1.0 mmol/L was observed, comparable to 2.5 mmol/L of standard GBCAs.
  • Standardized dilution series of gadolinium contrast agents were examined across key clinical sequences using 1.5, 3, and 7 Tesla MRI.
  • Finding indicates gadopiclenol can optimize MRI performance by allowing effective imaging with reduced gadolinium concentrations.

Cite This Study

Marth et al. (2025) studied this question.

synapsesocial.com/papers/68c23f1fb210217d6479517ahttps://doi.org/10.1016/j.ejrad.2025.112322
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1R1, R2 and R2* Relaxivity Measurements of the Contrast Agent Gadopiclenol in Human Blood; Application to Administration Strategies2025
  2. 2Pulmonary MR angiography with gadopiclenol can reduce gadolinium exposure while maintaining signal enhancement.2025
  3. 3Implementation of gadolinium saving potential utilizing Gadopiclenol in vasculitis imaging2025
  4. 4Quantitative characterization of background parenchymal enhancement in abbreviated breast MRI acquired with a high relaxivity contrast agent2025
  5. 5Current Status and Future Aspects of Gadolinium Oxide Nanoparticles as Positive Magnetic Resonance Imaging Contrast Agents2025